This second issue of Neurology® Neuroimmunology & Neuroinflammation incorporates examples of the types of reports that incarnate our mission: to inform and inspire the community of neuroinflammation and neuroimmunology researchers. Tran et al. report a phase I trial of LINGO antibodies, inaugurating clinical development of remyelination therapy for multiple sclerosis (MS), and the attainment of...

One of the most enduring models of human disease now celebrates the seventieth anniversary of its publication in The Journal of Experimental Medicine . Thomas Rivers, working at the Hospital of the Rockefeller Institute for Medical Research, along with his colleagues D.H. Sprunt and G.P. Berry, submitted the article entitled, “Observations on Attempts to Produce Disseminated Encephalomyelitis i...

Interleukin-17A (IL-17A) is founding member of a novel family of inflammatory cytokines that plays a critical role in the pathogenesis of many autoimmune diseases, including multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE). IL17A signals through IL-17RA, which is expressed in most peripheral tissues; however, expression of IL-17RA in the central nerv...